US5837284A
(en)
*
|
1995-12-04 |
1998-11-17 |
Mehta; Atul M. |
Delivery of multiple doses of medications
|
US6486177B2
(en)
*
|
1995-12-04 |
2002-11-26 |
Celgene Corporation |
Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
|
US5922736A
(en)
*
|
1995-12-04 |
1999-07-13 |
Celegene Corporation |
Chronic, bolus administration of D-threo methylphenidate
|
US8071128B2
(en)
|
1996-06-14 |
2011-12-06 |
Kyowa Hakko Kirin Co., Ltd. |
Intrabuccally rapidly disintegrating tablet and a production method of the tablets
|
US8022095B2
(en)
*
|
1996-08-16 |
2011-09-20 |
Pozen, Inc. |
Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
|
US6962997B1
(en)
*
|
1997-05-22 |
2005-11-08 |
Celgene Corporation |
Process and intermediates for resolving piperidyl acetamide steroisomers
|
US6322819B1
(en)
|
1998-10-21 |
2001-11-27 |
Shire Laboratories, Inc. |
Oral pulsed dose drug delivery system
|
AU2004200325B2
(en)
*
|
1998-10-21 |
2006-09-28 |
Shire Llc |
Oral Pulsed Dose Drug Delivery System
|
US20080102121A1
(en)
*
|
1998-11-02 |
2008-05-01 |
Elan Pharma International Limited |
Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
|
US20070122481A1
(en)
*
|
1998-11-02 |
2007-05-31 |
Elan Corporation Plc |
Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
|
US20090149479A1
(en)
*
|
1998-11-02 |
2009-06-11 |
Elan Pharma International Limited |
Dosing regimen
|
US20060240105A1
(en)
*
|
1998-11-02 |
2006-10-26 |
Elan Corporation, Plc |
Multiparticulate modified release composition
|
US20080113025A1
(en)
*
|
1998-11-02 |
2008-05-15 |
Elan Pharma International Limited |
Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
|
EP2020229A1
(de)
|
1998-11-02 |
2009-02-04 |
Elan Pharma International Limited |
Mehrpartikelmodifizierte Freisetzungszusammensetzung
|
US20090297602A1
(en)
*
|
1998-11-02 |
2009-12-03 |
Devane John G |
Modified Release Loxoprofen Compositions
|
US6673367B1
(en)
|
1998-12-17 |
2004-01-06 |
Euro-Celtique, S.A. |
Controlled/modified release oral methylphenidate formulations
|
US6419960B1
(en)
*
|
1998-12-17 |
2002-07-16 |
Euro-Celtique S.A. |
Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
|
US7083808B2
(en)
|
1998-12-17 |
2006-08-01 |
Euro-Celtique S.A. |
Controlled/modified release oral methylphenidate formulations
|
US6432448B1
(en)
|
1999-02-08 |
2002-08-13 |
Fmc Corporation |
Edible coating composition
|
US6723342B1
(en)
|
1999-02-08 |
2004-04-20 |
Fmc Corporation |
Edible coating composition
|
CA2366908A1
(en)
*
|
1999-03-24 |
2000-09-28 |
The Secretary Of State For Defence |
Vaccine composition
|
US20030170181A1
(en)
*
|
1999-04-06 |
2003-09-11 |
Midha Kamal K. |
Method for preventing abuse of methylphenidate
|
KR101216270B1
(ko)
|
1999-10-29 |
2012-12-31 |
유로-셀티크 소시에떼 아노뉨 |
서방성 하이드로코돈 제형
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
US6500462B1
(en)
*
|
1999-10-29 |
2002-12-31 |
Fmc Corporation |
Edible MCC/PGA coating composition
|
DE60115840T2
(de)
*
|
2000-01-19 |
2006-07-13 |
Mannkind Corp., Danbury |
Formulierung mit mehrfach gepulster wirkstofffreisetzung
|
US6544555B2
(en)
|
2000-02-24 |
2003-04-08 |
Advancis Pharmaceutical Corp. |
Antibiotic product, use and formulation thereof
|
EP1265598B1
(de)
*
|
2000-03-22 |
2006-08-02 |
The Secretary of State for Defence |
Arzneimittel zur verabreichung an schleimhäute
|
AU2001261434A1
(en)
*
|
2000-05-11 |
2001-11-26 |
Pharmacia Corporation |
Aldosterone antagonist composition for release during aldosterone acrophase
|
US6500457B1
(en)
*
|
2000-08-14 |
2002-12-31 |
Peirce Management, Llc |
Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
|
CA2420535A1
(en)
*
|
2000-08-30 |
2002-03-07 |
Mary Tanya Am Ende |
Sustained release formulations for growth hormone secretagogues
|
US20020068078A1
(en)
|
2000-10-13 |
2002-06-06 |
Rudnic Edward M. |
Antifungal product, use and formulation thereof
|
US6344215B1
(en)
*
|
2000-10-27 |
2002-02-05 |
Eurand America, Inc. |
Methylphenidate modified release formulations
|
CA2427815C
(en)
|
2000-10-30 |
2007-07-10 |
Euro-Celtique S.A. |
Controlled release hydrocodone formulations
|
IT1319655B1
(it)
|
2000-11-15 |
2003-10-23 |
Eurand Int |
Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
|
EP1339395A2
(de)
*
|
2000-11-28 |
2003-09-03 |
Fmc Corporation |
Essbare überzugszusammensetzung aus pga (propylenglykolalginat)
|
WO2002064654A1
(fr)
*
|
2001-02-09 |
2002-08-22 |
Reika Kogyo Kabushiki Kaisha |
Particule fonctionnelle, procede de preparation de celle-ci et procede de traitement par plasma
|
MXPA03008293A
(es)
*
|
2001-03-13 |
2003-12-11 |
Penwest Pharmaceuticals Co |
Formas de dosis cronoterapeuticas.
|
KR100982753B1
(ko)
*
|
2001-04-05 |
2010-09-16 |
콜라제넥스 파마슈티칼스, 인크 |
테트라사이클린 화합물 및 테트라사이클린 유도체의 전달조절
|
US8329216B2
(en)
*
|
2001-07-06 |
2012-12-11 |
Endo Pharmaceuticals Inc. |
Oxymorphone controlled release formulations
|
WO2003004032A1
(en)
*
|
2001-07-06 |
2003-01-16 |
Endo Pharmaceuticals, Inc. |
Oral administration of 6-hydroxy-oxymorphone for use as an analgesic
|
US20070254009A1
(en)
*
|
2001-07-13 |
2007-11-01 |
Flow Focusing, Inc. |
Antibiotic/bone morphogenic protein formulation and method of treatment
|
WO2003005996A1
(en)
*
|
2001-07-13 |
2003-01-23 |
Flow Focusing, Inc. |
Programmable controlled release injectable opioid formulation
|
US20060263401A1
(en)
*
|
2001-07-13 |
2006-11-23 |
Flow Focusing, Inc. |
Formulation and Method for Preventing Infection
|
US20070254008A1
(en)
*
|
2001-07-13 |
2007-11-01 |
Flow Focusing, Inc. |
Antibiotic formulation and method of treatment
|
US20040142013A1
(en)
*
|
2001-07-13 |
2004-07-22 |
Flow Focusing, Inc. |
Implantable orthopedic surgical devices with controlled release antimicrobial component
|
US20030055075A1
(en)
*
|
2001-07-13 |
2003-03-20 |
Rubsamen Reid M. |
Programmable controlled release injectable opioid formulation
|
WO2003013433A2
(en)
|
2001-08-06 |
2003-02-20 |
Euro-Celtique S.A. |
Sequestered antagonist formulations
|
DE60232417D1
(de)
|
2001-08-06 |
2009-07-02 |
Euro Celtique Sa |
Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
|
US20030044458A1
(en)
*
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
US20150031718A1
(en)
*
|
2001-08-06 |
2015-01-29 |
Purdue Pharma L.P. |
Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent
|
US20030068375A1
(en)
|
2001-08-06 |
2003-04-10 |
Curtis Wright |
Pharmaceutical formulation containing gelling agent
|
JP2005523876A
(ja)
*
|
2001-09-26 |
2005-08-11 |
ペンウェスト ファーマシューティカルズ カンパニー |
乱用の可能性が低減したオピオイド製剤
|
US9358214B2
(en)
|
2001-10-04 |
2016-06-07 |
Adare Pharmaceuticals, Inc. |
Timed, sustained release systems for propranolol
|
US8101209B2
(en)
*
|
2001-10-09 |
2012-01-24 |
Flamel Technologies |
Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
|
FR2830447B1
(fr)
*
|
2001-10-09 |
2004-04-16 |
Flamel Tech Sa |
Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
|
AUPR839001A0
(en)
*
|
2001-10-19 |
2001-11-15 |
Eli Lilly And Company |
Dosage form, device and methods of treatment
|
ES2351303T3
(es)
*
|
2001-12-11 |
2011-02-02 |
University Of Virginia Patent Foundation |
Utilización de pramipexol para el tratamiento de la esclerosis lateral amiotrófica.
|
US20060281797A1
(en)
*
|
2001-12-11 |
2006-12-14 |
University Of Virginia Patent Foundation |
Neurorestoration with R(+) Pramipexole
|
US6663888B2
(en)
*
|
2001-12-14 |
2003-12-16 |
Eurand Pharmaceuticals Ltd. |
Pulsatile release histamine H2 antagonist dosage form
|
US20050025824A1
(en)
*
|
2001-12-14 |
2005-02-03 |
Eurand Pharmaceuticals Ltd. |
Pulsatile release histamine H2 antagonist dosage form
|
JP2005527508A
(ja)
*
|
2002-03-07 |
2005-09-15 |
ヴェクトゥラ リミテッド |
経口デリバリー用急速溶融多粒子製剤
|
MXPA04009968A
(es)
|
2002-04-09 |
2004-12-13 |
Flamel Tech Sa |
Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s).
|
US7910133B2
(en)
*
|
2002-04-09 |
2011-03-22 |
Flamel Technologies |
Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillin
|
US7053034B2
(en)
*
|
2002-04-10 |
2006-05-30 |
Salvona, Llc |
Targeted controlled delivery compositions activated by changes in pH or salt concentration
|
CA2395819A1
(en)
*
|
2002-08-13 |
2004-02-13 |
Bernard Charles Sherman |
Dual-spike release formulation for oral drug delivery
|
US7445796B2
(en)
*
|
2002-08-19 |
2008-11-04 |
L. Perrigo Company |
Pharmaceutically active particles of a monomodal particle size distribution and method
|
AU2003296852A1
(en)
*
|
2002-09-18 |
2004-05-04 |
Elan Corporation, Plc |
Multiparticulate modified release composition comprising beraprost
|
US6913768B2
(en)
*
|
2002-09-24 |
2005-07-05 |
Shire Laboratories, Inc. |
Sustained release delivery of amphetamine salts
|
US20080220074A1
(en)
*
|
2002-10-04 |
2008-09-11 |
Elan Corporation Plc |
Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
|
MY148805A
(en)
*
|
2002-10-16 |
2013-05-31 |
Takeda Pharmaceutical |
Controlled release preparation
|
US20050191244A1
(en)
*
|
2002-10-25 |
2005-09-01 |
Gruenenthal Gmbh |
Abuse-resistant pharmaceutical dosage form
|
BR0315731A
(pt)
*
|
2002-10-30 |
2005-09-06 |
Pharmacia Corp |
Comprimidos orais de liberação prolongada e métodos para fabricar e usar os mesmos
|
US20050038042A1
(en)
*
|
2002-11-15 |
2005-02-17 |
Jenet Codd |
Modified release composition comprising a short-acting hypnotic for treatment of sleep disorders
|
GB0228571D0
(en)
|
2002-12-06 |
2003-01-15 |
Novartis Ag |
Organic compounds
|
US7988993B2
(en)
|
2002-12-09 |
2011-08-02 |
Andrx Pharmaceuticals, Inc. |
Oral controlled release dosage form
|
ES2553136T3
(es)
|
2002-12-13 |
2015-12-04 |
Durect Corporation |
Sistema de administración oral de fármacos que comprende materiales vehículos líquidos de alta viscosidad
|
US20040224020A1
(en)
*
|
2002-12-18 |
2004-11-11 |
Schoenhard Grant L. |
Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
|
US7332183B2
(en)
*
|
2002-12-26 |
2008-02-19 |
Pozen Inc. |
Multilayer dosage forms containing NSAIDs and triptans
|
US8367111B2
(en)
|
2002-12-31 |
2013-02-05 |
Aptalis Pharmatech, Inc. |
Extended release dosage forms of propranolol hydrochloride
|
US7153526B2
(en)
*
|
2003-02-26 |
2006-12-26 |
Frank Steven R |
Treatment of gastrointestinal infections
|
US20050152967A1
(en)
*
|
2003-03-28 |
2005-07-14 |
Pfab, Lp |
Dynamic variable release
|
US20050137265A1
(en)
*
|
2003-03-31 |
2005-06-23 |
Haley Eugene T. |
Rapidly dissolving metoclopramide solid oral dosage and method thereof
|
US20040192781A1
(en)
*
|
2003-03-31 |
2004-09-30 |
Haley Eugene T. |
Method of administration for metoclopramide and pharmaceutical formulation therefor
|
CA2520321A1
(en)
*
|
2003-04-04 |
2004-10-14 |
Pharmacia Corporation |
Oral extended release compressed tablets of multiparticulates
|
US7749532B2
(en)
|
2003-04-07 |
2010-07-06 |
Supernus Pharmaceuticals, Inc. |
Once daily formulations of tetracyclines
|
US20060105036A1
(en)
|
2003-05-12 |
2006-05-18 |
Stephen Peroutka |
Threo-dops controlled release formulation
|
US8158149B2
(en)
*
|
2004-05-12 |
2012-04-17 |
Chelsea Therapeutics, Inc. |
Threo-DOPS controlled release formulation
|
US8802139B2
(en)
|
2003-06-26 |
2014-08-12 |
Intellipharmaceutics Corp. |
Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
|
EP1648418A4
(de)
|
2003-07-21 |
2011-11-16 |
Middlebrook Pharmaceuticals Inc |
Antibiotisches produkt, seine verwendung und formulierung
|
AU2004258949B2
(en)
|
2003-07-21 |
2011-02-10 |
Shionogi, Inc. |
Antibiotic product, use and formulation thereof
|
CA2533292C
(en)
|
2003-07-21 |
2013-12-31 |
Advancis Pharmaceutical Corporation |
Antibiotic product, use and formulation thereof
|
JP2007502296A
(ja)
|
2003-08-11 |
2007-02-08 |
アドバンシス ファーマスーティカル コーポレイション |
ロバストペレット
|
AU2004264356B2
(en)
|
2003-08-12 |
2011-01-27 |
Shionogi, Inc. |
Antibiotic product, use and formulation thereof
|
WO2005016317A1
(en)
*
|
2003-08-19 |
2005-02-24 |
Themis Laboratories Private Limited |
Process for manufacture of extended release pellets containing diltiazem hci
|
US8246996B2
(en)
|
2003-08-29 |
2012-08-21 |
Shionogi Inc. |
Antibiotic product, use and formulation thereof
|
EP2260834A2
(de)
|
2003-09-03 |
2010-12-15 |
Mallinckrodt Inc. |
Granuläres Präparat zur verzögerten Freisetzung und seine Herstellung
|
US8460710B2
(en)
|
2003-09-15 |
2013-06-11 |
Shionogi, Inc. |
Antibiotic product, use and formulation thereof
|
US7906125B2
(en)
*
|
2003-09-18 |
2011-03-15 |
Boston Scientific Scimed, Inc. |
Solid or semi-solid therapeutic formulations
|
US8389008B2
(en)
*
|
2003-09-19 |
2013-03-05 |
Penwest Pharmaceuticals Co. |
Delayed release dosage forms
|
MXPA06003101A
(es)
|
2003-09-19 |
2006-06-20 |
Penwest Pharmaceuticals Co |
Formas de dosis cronoterapeuticas.
|
US20050226927A1
(en)
*
|
2004-04-02 |
2005-10-13 |
Impax Laboratories, Inc. |
Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
|
US20050220873A1
(en)
*
|
2004-04-02 |
2005-10-06 |
Chien-Hsuan Han |
Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist
|
US8007827B2
(en)
*
|
2004-04-02 |
2011-08-30 |
Impax Laboratories, Inc. |
Pharmaceutical dosage forms having immediate release and/or controlled release properties
|
US20050239830A1
(en)
*
|
2004-04-26 |
2005-10-27 |
Vikram Khetani |
Methods of diminishing co-abuse potential
|
WO2006009602A2
(en)
|
2004-06-16 |
2006-01-26 |
Tap Pharmaceutical Products, Inc. |
Multiple ppi dosage form
|
US8394409B2
(en)
*
|
2004-07-01 |
2013-03-12 |
Intellipharmaceutics Corp. |
Controlled extended drug release technology
|
EP1771158A4
(de)
|
2004-07-02 |
2008-03-12 |
Advancis Pharmaceutical Corp |
Tablette für pulsierte abgabe
|
US10624858B2
(en)
|
2004-08-23 |
2020-04-21 |
Intellipharmaceutics Corp |
Controlled release composition using transition coating, and method of preparing same
|
EP2036546B1
(de)
*
|
2004-08-23 |
2018-10-10 |
PEJO Iserlohn Heilmittel-und Diät-GmbH & Co.KG |
Psychostimulantium mit einer pharmazeutischen Zusammensetzung
|
US9149472B2
(en)
|
2004-08-31 |
2015-10-06 |
Jack William Schultz |
Controlled release compositions for treatment of cognitive, emotional and mental ailments and disorders
|
US8747895B2
(en)
|
2004-09-13 |
2014-06-10 |
Aptalis Pharmatech, Inc. |
Orally disintegrating tablets of atomoxetine
|
GB0421121D0
(en)
*
|
2004-09-22 |
2004-10-27 |
Natrocell Technologies Ltd |
Composite rodenticide
|
US8312836B2
(en)
|
2004-09-28 |
2012-11-20 |
Atrium Medical Corporation |
Method and apparatus for application of a fresh coating on a medical device
|
US8367099B2
(en)
|
2004-09-28 |
2013-02-05 |
Atrium Medical Corporation |
Perforated fatty acid films
|
US9801982B2
(en)
|
2004-09-28 |
2017-10-31 |
Atrium Medical Corporation |
Implantable barrier device
|
WO2006037080A2
(en)
|
2004-09-28 |
2006-04-06 |
Atrium Medical Corporation |
Uv cured gel and method of making
|
US8001922B2
(en)
|
2004-09-28 |
2011-08-23 |
Atrium Medical Corporation |
Application of a coating on a medical device
|
US9012506B2
(en)
|
2004-09-28 |
2015-04-21 |
Atrium Medical Corporation |
Cross-linked fatty acid-based biomaterials
|
US9000040B2
(en)
|
2004-09-28 |
2015-04-07 |
Atrium Medical Corporation |
Cross-linked fatty acid-based biomaterials
|
US9884014B2
(en)
|
2004-10-12 |
2018-02-06 |
Adare Pharmaceuticals, Inc. |
Taste-masked pharmaceutical compositions
|
US20060078621A1
(en)
*
|
2004-10-13 |
2006-04-13 |
Wedinger Robert S |
Method of providing customized drug delivery systems
|
ES2409347T3
(es)
|
2004-10-21 |
2013-06-26 |
Aptalis Pharmatech, Inc. |
Composiciones farmacéuticas de sabor enmascarado con agentes porogénicos gastrosolubles
|
AR052225A1
(es)
*
|
2004-11-04 |
2007-03-07 |
Astrazeneca Ab |
Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones
|
AR051654A1
(es)
*
|
2004-11-04 |
2007-01-31 |
Astrazeneca Ab |
Nuevas formulaciones de pellets de liberacion modificada para inhibidores de la bomba de protones
|
US20060105038A1
(en)
*
|
2004-11-12 |
2006-05-18 |
Eurand Pharmaceuticals Limited |
Taste-masked pharmaceutical compositions prepared by coacervation
|
EP2623095A1
(de)
*
|
2004-11-16 |
2013-08-07 |
Elan Pharma International Limited |
Injizierbare Olanzapin-Formulierungen in Nanoteilchenform
|
US20060121112A1
(en)
*
|
2004-12-08 |
2006-06-08 |
Elan Corporation, Plc |
Topiramate pharmaceutical composition
|
KR20070087643A
(ko)
*
|
2004-12-09 |
2007-08-28 |
셀진 코포레이션 |
D-트레오 메틸페니데이트를 이용한 치료
|
KR20070116581A
(ko)
*
|
2004-12-15 |
2007-12-10 |
엘란 파마 인터내셔널 리미티드 |
나노입자형 타크롤리무스 제제
|
US20060269596A1
(en)
*
|
2005-01-12 |
2006-11-30 |
Gary Liversidge |
Controlled release compositions comprising an acylanilide
|
EP1846382A2
(de)
*
|
2005-01-26 |
2007-10-24 |
Elan Pharma International Limited |
Ein antipsychotikum enthaltende zsuammensetzungen mit gesteuerter freisetzung
|
GB0501809D0
(en)
*
|
2005-01-28 |
2005-03-09 |
Pharmakodex Ltd |
Anti-migraine formulations
|
FR2884145A1
(fr)
*
|
2005-04-06 |
2006-10-13 |
Flamel Technologies Sa |
Forme pharmaceutique orale de losartan
|
FR2882260A1
(fr)
*
|
2005-02-21 |
2006-08-25 |
Flamel Technologies Sa |
Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
|
CA2598410A1
(fr)
*
|
2005-02-21 |
2006-08-24 |
Flamel Technologies |
Forme pharmaceutique orale de losartan
|
FR2882259A1
(fr)
*
|
2005-02-21 |
2006-08-25 |
Flamel Technologies Sa |
Forme pharmaceutique orale multimicroparticulaire a liberation modifiee de losartan
|
EP1855651A4
(de)
*
|
2005-03-03 |
2011-06-15 |
Elan Pharma Int Ltd |
Nanopartikelzusammensetzungen heterocyclischer amidderivate
|
WO2006102964A2
(en)
*
|
2005-03-29 |
2006-10-05 |
Evonik Röhm Gmbh |
Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release
|
CA2604192A1
(en)
*
|
2005-04-12 |
2006-10-19 |
Elan Pharma International Limited |
Modified release compositions comprising a fluorocytidine derivative for the treatment of cancer
|
WO2006110802A1
(en)
*
|
2005-04-12 |
2006-10-19 |
Elan Pharma International Limited |
Nanoparticulate and controlled release compositions comprising cyclosporine
|
AU2006235483B2
(en)
*
|
2005-04-12 |
2010-11-25 |
Elan Pharma International Limited |
Controlled release compositions comprising a cephalosporin for the treatment of a bacterial infection
|
US20090252807A1
(en)
*
|
2005-04-13 |
2009-10-08 |
Elan Pharma International Limited |
Nanoparticulate and Controlled Release Compositions Comprising Prostaglandin Derivatives
|
US9161918B2
(en)
|
2005-05-02 |
2015-10-20 |
Adare Pharmaceuticals, Inc. |
Timed, pulsatile release systems
|
JP2009514989A
(ja)
*
|
2005-05-10 |
2009-04-09 |
エラン コーポレーション ピーエルシー |
改変放出ロキソプロフェン組成物
|
US20090269400A1
(en)
*
|
2005-05-16 |
2009-10-29 |
Elan Pharma International Limited |
Nanoparticulate and Controlled Release Compositions Comprising a Cephalosporin
|
KR20080047509A
(ko)
*
|
2005-05-23 |
2008-05-29 |
엘란 파마 인터내셔널 리미티드 |
혈소판 응집 억제제를 함유하는 나노입자형 조절 방출조성물
|
EP1954253A4
(de)
|
2005-06-08 |
2011-07-27 |
Elan Pharma Int Ltd |
Nanoteilchenförmige und kontrolliert freigesetzte zusammensetzungen mit cefditoren
|
US20100136106A1
(en)
*
|
2005-06-08 |
2010-06-03 |
Gary Liversidge |
Modified Release Famciclovir Compositions
|
JP2009516636A
(ja)
*
|
2005-06-13 |
2009-04-23 |
エラン コーポレーション ピーエルシー |
改変放出チクロピジン組成物
|
US8263561B2
(en)
|
2005-06-16 |
2012-09-11 |
Amana Pharmaceuticals Corp. |
Composition and method for inhibiting, preventing, or ameliorating complications associated with ingestion of a medicinal, chemical, or biological substance or agent
|
WO2007027273A1
(en)
*
|
2005-06-20 |
2007-03-08 |
Elan Pharma International Limited |
Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds
|
JP5095615B2
(ja)
|
2005-06-27 |
2012-12-12 |
バリアント・インターナショナル・(バルバドス)・ソサイアティーズ・ウィズ・リストリクティッド・ライアビリティ |
ブプロピオン塩の放出調整製剤
|
US8784851B2
(en)
*
|
2005-07-28 |
2014-07-22 |
University Of Hull |
Topical formulations containing sporopollenin
|
US8778395B2
(en)
*
|
2005-08-11 |
2014-07-15 |
Andrx Labs, Llc |
Diltiazem controlled release formulation and method of manufacture
|
AU2006279643B2
(en)
*
|
2005-08-15 |
2010-06-17 |
University Of Virginia Patent Foundation |
Neurorestoration with R(+) pramipexole
|
US9427423B2
(en)
|
2009-03-10 |
2016-08-30 |
Atrium Medical Corporation |
Fatty-acid based particles
|
US9278161B2
(en)
|
2005-09-28 |
2016-03-08 |
Atrium Medical Corporation |
Tissue-separating fatty acid adhesion barrier
|
FR2891459B1
(fr)
*
|
2005-09-30 |
2007-12-28 |
Flamel Technologies Sa |
Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
|
KR20080080094A
(ko)
*
|
2005-10-14 |
2008-09-02 |
하. 룬트벡 아크티에 셀스카브 |
에스시탈로프람 및 부프로피온의 저용량 조합물을 이용한중추신경계 장애의 치료 방법
|
AU2006304889A1
(en)
*
|
2005-10-14 |
2007-04-26 |
H. Lundbeck A/S |
Stable pharmaceutical formulations containing escitalopram and bupropion
|
JP2009511215A
(ja)
|
2005-10-15 |
2009-03-19 |
アトリウム メディカル コーポレーション |
生体吸収性薬物担体コーティング用の疎水性架橋ゲル
|
US20070098796A1
(en)
*
|
2005-10-31 |
2007-05-03 |
Rekhi Gurvinder S |
Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochrloride
|
US20070098791A1
(en)
*
|
2005-10-31 |
2007-05-03 |
Rekhi Gurvinder S |
Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride
|
WO2007062266A2
(en)
*
|
2005-11-28 |
2007-05-31 |
Marinus Pharmaceuticals |
Ganaxolone formulations and methods for the making and use thereof
|
US8357394B2
(en)
|
2005-12-08 |
2013-01-22 |
Shionogi Inc. |
Compositions and methods for improved efficacy of penicillin-type antibiotics
|
US8778924B2
(en)
|
2006-12-04 |
2014-07-15 |
Shionogi Inc. |
Modified release amoxicillin products
|
US20070134322A1
(en)
*
|
2005-12-14 |
2007-06-14 |
Forest Laboratories, Inc. |
Modified and pulsatile release pharmaceutical formulations of escitalopram
|
US20070141147A1
(en)
*
|
2005-12-21 |
2007-06-21 |
Auriga Laboratories, Inc. |
Sequential release pharmaceutical formulations
|
US10064828B1
(en)
|
2005-12-23 |
2018-09-04 |
Intellipharmaceutics Corp. |
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
KR100762847B1
(ko)
*
|
2006-01-27 |
2007-10-04 |
씨제이 주식회사 |
멀티플 유닛 타입 서방성 경구 제제 및 그 제조방법
|
EP1976491B1
(de)
*
|
2006-01-27 |
2014-12-17 |
Aptalis Pharmatech, Inc. |
Wirkstofffreisetzungssysteme mit einem leicht basischen selektiven serotonin-5-blockierungsmittel und organischen säuren
|
KR100753480B1
(ko)
*
|
2006-01-27 |
2007-08-31 |
씨제이 주식회사 |
잘토프로펜 함유 서방성 정제 및 그 제조방법
|
KR20140088230A
(ko)
|
2006-01-27 |
2014-07-09 |
앱탈리스 파마테크, 인코포레이티드 |
약 염기성 약물과 유기산을 포함하는 약물 전달 시스템
|
DK1993357T3
(da)
|
2006-02-09 |
2014-04-22 |
Alba Therapeutics Corp |
Formuleringer af en tight junction effektor
|
US20070212414A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Penwest Pharmaceuticals Co. |
Ethanol-resistant sustained release formulations
|
KR20070091960A
(ko)
*
|
2006-03-08 |
2007-09-12 |
주식회사종근당 |
졸피뎀 또는 그의 염을 포함하는 안전한 제어방출형 제제조성물
|
DK2428205T3
(da)
|
2006-03-16 |
2012-10-22 |
Tris Pharma Inc |
Modificerede formuleringer indeholdende lægemiddel-ionbytterharpikskomplekser
|
CN104825397A
(zh)
*
|
2006-04-03 |
2015-08-12 |
伊萨·奥迪迪 |
含有机溶胶涂层的受控释放递送物件
|
US8518926B2
(en)
*
|
2006-04-10 |
2013-08-27 |
Knopp Neurosciences, Inc. |
Compositions and methods of using (R)-pramipexole
|
US20070253927A1
(en)
*
|
2006-04-13 |
2007-11-01 |
Gwenaelle Jegou |
Cosmetic compositions comprising at least one dielectrophile monomer and at least one radical initiator
|
EP2010161A2
(de)
*
|
2006-04-17 |
2009-01-07 |
Actavis Group PTC HF |
Formulierung für orale darreichungsformen und verfahren für ihre zubereitung
|
US8299052B2
(en)
|
2006-05-05 |
2012-10-30 |
Shionogi Inc. |
Pharmaceutical compositions and methods for improved bacterial eradication
|
US10960077B2
(en)
|
2006-05-12 |
2021-03-30 |
Intellipharmaceutics Corp. |
Abuse and alcohol resistant drug composition
|
US8846100B2
(en)
|
2006-05-12 |
2014-09-30 |
Shire Llc |
Controlled dose drug delivery system
|
KR20090021169A
(ko)
|
2006-05-16 |
2009-02-27 |
크놉 뉴로사이언시스 인코포레이티드 |
R(+) 및 s(-) 프라미펙솔을 포함하는 조성물 및 이의 사용 방법
|
WO2007136664A2
(en)
*
|
2006-05-16 |
2007-11-29 |
Flow Focusing, Inc. |
Antibiotic formulation and method of treatment
|
US20080069891A1
(en)
|
2006-09-15 |
2008-03-20 |
Cima Labs, Inc. |
Abuse resistant drug formulation
|
BRPI0713447A2
(pt)
*
|
2006-06-23 |
2012-03-13 |
Elan Pharma International Limited |
composição forma de dosagem oral sólida, e, método para o tratamento de dor
|
AU2007260822B2
(en)
*
|
2006-06-23 |
2012-07-05 |
Alkermes Pharma Ireland Limited |
Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
|
BRPI0714173A2
(pt)
*
|
2006-07-12 |
2012-12-25 |
Elan Pharma Int Ltd |
composiÇço nanoparticulada estÁvel,mÉtodos para preparar a composiÇço, para prevenir e/ou tratar estados de doenÇas, sintomas, sÍndromes e condiÇÕes do sistema nervoso central, para melhorar ou manter a biodisponibilidade de modafinil, e para tratar distérbio com base neurolàgica, composiÇço farmacÊutica, e forma de dosagem
|
AU2007275034A1
(en)
*
|
2006-07-21 |
2008-01-24 |
Lab International Srl |
Hydrophilic abuse deterrent delivery system
|
US8889184B2
(en)
*
|
2006-09-07 |
2014-11-18 |
Losan Pharma Gmbh |
Particulate form of a pharmaceutical composition which is easy to swallow
|
WO2008027557A2
(en)
*
|
2006-08-31 |
2008-03-06 |
Spherics, Inc. |
Topiramate compositions and methods of enhancing its bioavailability
|
MX370905B
(es)
*
|
2006-08-31 |
2020-01-09 |
Adare Pharmaceuticals Inc |
Sistema de distribucion de farmacos, que comprenden soluciones solidas de farmacos debilmente basicos.
|
US20080064694A1
(en)
*
|
2006-09-11 |
2008-03-13 |
Auriga Laboratories, Inc. |
Multi-Phase Release Methscopolamine Compositions
|
US8445018B2
(en)
|
2006-09-15 |
2013-05-21 |
Cima Labs Inc. |
Abuse resistant drug formulation
|
WO2008033155A1
(en)
*
|
2006-09-15 |
2008-03-20 |
Auriga Laboratories, Inc. |
Kits for prevention and treatment of rhinitis
|
US20080081067A1
(en)
*
|
2006-10-03 |
2008-04-03 |
Gupta Manishkumar |
Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
|
US20080085312A1
(en)
*
|
2006-10-04 |
2008-04-10 |
Auriga Laboratories, Inc. |
Multi-Phase Release Potassium Guaiacolsulfonate Compositions
|
US20090069247A1
(en)
*
|
2006-10-06 |
2009-03-12 |
Blake Paterson |
Use of tight junction antagonists to treat inflammatory bowel disease
|
ES2524556T3
(es)
|
2006-10-09 |
2014-12-10 |
Charleston Laboratories, Inc. |
Composiciones farmacéuticas
|
WO2008052185A2
(en)
|
2006-10-26 |
2008-05-02 |
Alba Therapeutics Corp |
Materials and methods for the treatment of celiac disease
|
US20110212175A1
(en)
*
|
2006-10-30 |
2011-09-01 |
Hanall Biopharma Co., Ltd. |
Combination preparation comprising angiotensin-ii-receptor blocker and hmg-coa reductase inhibitor
|
US8394845B2
(en)
*
|
2006-10-30 |
2013-03-12 |
Hanall Biopharma Co., Ltd. |
Method of using combination preparation comprising angiotensin-II-receptor blocker and HMG-CoA reductase inhibitor
|
CN101528204B
(zh)
*
|
2006-10-30 |
2012-12-12 |
韩诺生物制约株式会社 |
包含血管紧张素Ⅱ受体阻断剂和HMG-CoA还原酶抑制剂的控释复合组合物
|
JP2010508897A
(ja)
|
2006-11-06 |
2010-03-25 |
アトリウム メディカル コーポレーション |
コーティングされた外科用メッシュ
|
US9492596B2
(en)
|
2006-11-06 |
2016-11-15 |
Atrium Medical Corporation |
Barrier layer with underlying medical device and one or more reinforcing support structures
|
AU2007319141B2
(en)
|
2006-11-17 |
2013-01-10 |
Supernus Pharmaceuticals Inc. |
Sustained-release formulations of topiramate
|
CA2669410C
(en)
|
2006-11-21 |
2015-07-14 |
Mcneil-Ppc, Inc. |
Modified release analgesic suspensions
|
KR20090091321A
(ko)
*
|
2006-11-28 |
2009-08-27 |
마리누스 파마슈티컬스 |
나노입자 제형, 이의 제조방법 및 이의 용도
|
EP2363113B1
(de)
*
|
2006-12-04 |
2017-08-02 |
Supernus Pharmaceuticals, Inc. |
Topiramat-Formulierungen für verstärkte unmittelbare Freisetzung
|
US8524695B2
(en)
*
|
2006-12-14 |
2013-09-03 |
Knopp Neurosciences, Inc. |
Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
|
NZ598477A
(en)
|
2007-02-20 |
2012-11-30 |
Aptalis Pharma Ltd |
Stable digestive enzyme compositions
|
US20080227805A1
(en)
*
|
2007-02-28 |
2008-09-18 |
Abbott Laboratories |
Sustained release parenteral formulations of buprenorphine
|
EP2137171A4
(de)
|
2007-03-14 |
2010-05-19 |
Knopp Neurosciences Inc |
Synthese von chiralaufgereinigten substituierten benzothiazoldiaminen
|
US9833510B2
(en)
*
|
2007-06-12 |
2017-12-05 |
Johnson & Johnson Consumer Inc. |
Modified release solid or semi-solid dosage forms
|
US20080318993A1
(en)
*
|
2007-06-21 |
2008-12-25 |
Endo Pharmaceuticals, Inc. |
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Hepatic Impairment
|
US20080318994A1
(en)
|
2007-06-21 |
2008-12-25 |
Endo Pharmaceuticals, Inc. |
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment
|
US20090124650A1
(en)
*
|
2007-06-21 |
2009-05-14 |
Endo Pharmaceuticals, Inc. |
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
|
US20090060983A1
(en)
*
|
2007-08-30 |
2009-03-05 |
Bunick Frank J |
Method And Composition For Making An Orally Disintegrating Dosage Form
|
WO2009058798A2
(en)
|
2007-10-31 |
2009-05-07 |
Mcneil-Ppc, Inc. |
Orally disintegrated dosage form
|
AU2008335809A1
(en)
|
2007-12-06 |
2009-06-18 |
Durect Corporation |
Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
|
KR101569604B1
(ko)
|
2007-12-28 |
2015-11-16 |
임팩스 라보라토리즈, 인코포레이티드 |
레보도파 방출 제어형 제제 및 이의 용도
|
EP3090743A1
(de)
|
2008-01-09 |
2016-11-09 |
Charleston Laboratories, Inc. |
Pharmazeutische zusammensetzungen
|
US20100137442A2
(en)
*
|
2008-02-01 |
2010-06-03 |
Xenoport, Inc. |
Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment
|
WO2009109856A2
(en)
|
2008-03-07 |
2009-09-11 |
Axcan Pharma Inc. |
Method for detecting infectious parvovirus in pharmaceutical preparations
|
US8372432B2
(en)
|
2008-03-11 |
2013-02-12 |
Depomed, Inc. |
Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
|
CA2720108C
(en)
*
|
2008-03-11 |
2016-06-07 |
Depomed, Inc. |
Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
|
US8133506B2
(en)
*
|
2008-03-12 |
2012-03-13 |
Aptalis Pharmatech, Inc. |
Drug delivery systems comprising weakly basic drugs and organic acids
|
CA2627198A1
(en)
*
|
2008-03-27 |
2009-09-27 |
Pharmascience Inc. |
Methylphenidate extended release therapeutic drug delivery system
|
US20090311335A1
(en)
*
|
2008-06-12 |
2009-12-17 |
Scott Jenkins |
Combination of a triptan and an nsaid
|
GB0812513D0
(en)
*
|
2008-07-09 |
2008-08-13 |
Univ Hull |
Delivery vehicle
|
JP2012500283A
(ja)
|
2008-08-19 |
2012-01-05 |
ノップ ニューロサイエンシーズ、インク. |
(r)−プラミペキソールを使用した組成物並びにその方法
|
DE102008048729A1
(de)
*
|
2008-09-24 |
2010-03-25 |
Add Technologies Ltd Advanced Drug Delivery |
Multipartikuläre Tabletten und Verfahren zur deren Herstellung
|
US20100260844A1
(en)
|
2008-11-03 |
2010-10-14 |
Scicinski Jan J |
Oral pharmaceutical dosage forms
|
AU2009311877C1
(en)
*
|
2008-11-07 |
2013-08-15 |
Samyang Holdings Corporation |
Pharmaceutical composition for release control of methylphenidate
|
WO2010053337A2
(ko)
*
|
2008-11-10 |
2010-05-14 |
(주)아모레퍼시픽 |
서방성 미립자 및 이의 제조방법
|
US8551517B2
(en)
*
|
2008-12-16 |
2013-10-08 |
Kimberly-Clark Worldwide, Inc. |
Substrates providing multiple releases of active agents
|
WO2010078486A2
(en)
|
2008-12-31 |
2010-07-08 |
Upsher-Smith Laboratories, Inc. |
Opioid-containing oral pharmaceutical compositions and methods
|
DK2395840T3
(da)
|
2009-02-13 |
2020-06-08 |
Romark Laboratories Lc |
Farmaceutiske formuleringer af nitazoxanid med kontrolleret frigivelse
|
DK3045043T3
(da)
|
2009-02-26 |
2020-08-03 |
Relmada Therapeutics Inc |
Orale farmaceutiske sammensætninger af 3-hydroxy-n-methylmorphinan med forlænget frigivelse og fremgangsmåde til anvendelse
|
SG175137A1
(en)
*
|
2009-04-09 |
2011-11-28 |
Alkermes Pharma Ireland Ltd |
Drug delivery composition
|
KR20120022984A
(ko)
*
|
2009-04-21 |
2012-03-12 |
셀렉타 바이오사이언시즈, 인크. |
Th1 편향 반응을 제공하는 면역나노치료법
|
MX360019B
(es)
*
|
2009-04-24 |
2018-10-15 |
Iceutica Pty Ltd |
Una formulación novedosa de metaxalona.
|
EA201791383A1
(ru)
|
2009-05-27 |
2018-06-29 |
Селекта Байосайенсиз, Инк. |
Наноносители, имеющие компоненты с различными скоростями высвобождения
|
US20110003005A1
(en)
*
|
2009-07-06 |
2011-01-06 |
Gopi Venkatesh |
Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
|
CA2767576C
(en)
|
2009-07-08 |
2020-03-10 |
Charleston Laboratories Inc. |
Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
|
TW201117812A
(en)
|
2009-08-05 |
2011-06-01 |
Idenix Pharmaceuticals Inc |
Macrocyclic serine protease inhibitors
|
US20110038910A1
(en)
|
2009-08-11 |
2011-02-17 |
Atrium Medical Corporation |
Anti-infective antimicrobial-containing biomaterials
|
US20110052685A1
(en)
*
|
2009-08-31 |
2011-03-03 |
Depomed, Inc. |
Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen
|
BR112012008317A2
(pt)
|
2009-09-17 |
2016-03-22 |
Upsher Smith Lab Inc |
produto de liberação sustentada compreendendo uma combinação de uma amina não-opioide e uma droga anti-inflamatória não-esteroidal
|
US20110318411A1
(en)
|
2010-06-24 |
2011-12-29 |
Luber Joseph R |
Multi-layered orally disintegrating tablet and the manufacture thereof
|
US8343533B2
(en)
*
|
2009-09-24 |
2013-01-01 |
Mcneil-Ppc, Inc. |
Manufacture of lozenge product with radiofrequency
|
US20110070286A1
(en)
*
|
2009-09-24 |
2011-03-24 |
Andreas Hugerth |
Process for the manufacture of nicotine-comprising chewing gum and nicotine-comprising chewing gum manufactured according to said process
|
US8313768B2
(en)
|
2009-09-24 |
2012-11-20 |
Mcneil-Ppc, Inc. |
Manufacture of tablet having immediate release region and sustained release region
|
WO2011056764A1
(en)
|
2009-11-05 |
2011-05-12 |
Ambit Biosciences Corp. |
Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
|
EP2506836B1
(de)
|
2009-12-02 |
2018-02-14 |
Adare Pharmaceuticals S.R.L. |
Fexofenadin-mikrokapseln und zusammensetzungen damit
|
MY159958A
(en)
|
2009-12-18 |
2017-02-15 |
Idenix Pharmaceuticals Inc |
5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
|
US8597681B2
(en)
|
2009-12-22 |
2013-12-03 |
Mallinckrodt Llc |
Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
|
US9198861B2
(en)
|
2009-12-22 |
2015-12-01 |
Mallinckrodt Llc |
Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
|
WO2011094890A1
(en)
|
2010-02-02 |
2011-08-11 |
Argusina Inc. |
Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
|
WO2011112689A2
(en)
|
2010-03-11 |
2011-09-15 |
Ambit Biosciences Corp. |
Saltz of an indazolylpyrrolotriazine
|
US9186642B2
(en)
|
2010-04-28 |
2015-11-17 |
The Procter & Gamble Company |
Delivery particle
|
US9993793B2
(en)
|
2010-04-28 |
2018-06-12 |
The Procter & Gamble Company |
Delivery particles
|
WO2011143120A1
(en)
|
2010-05-11 |
2011-11-17 |
Cima Labs Inc. |
Alcoholres i stant metoprolol - containing extended - release oral dosage forms
|
WO2011146583A2
(en)
|
2010-05-19 |
2011-11-24 |
Elan Pharma International Limited |
Nanoparticulate cinacalcet formulations
|
NO2575876T3
(de)
|
2010-05-26 |
2018-05-05 |
|
|
MY167126A
(en)
*
|
2010-06-16 |
2018-08-13 |
Takeda Pharmaceuticals Usa Inc |
Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
|
EP2593141B1
(de)
|
2010-07-16 |
2018-07-04 |
Atrium Medical Corporation |
Zusammensetzung und verfahren zur veränderung der geschwindigkeit einer hydrolyse ausgehärteter materialien auf ölbasis
|
US9907767B2
(en)
|
2010-08-03 |
2018-03-06 |
Velicept Therapeutics, Inc. |
Pharmaceutical compositions and the treatment of overactive bladder
|
WO2012030885A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Hydrobromide salts of a pyrazolylaminoquinazoline
|
US8703943B2
(en)
|
2010-09-01 |
2014-04-22 |
Ambit Biosciences Corporation |
Optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
|
CN101933913A
(zh)
*
|
2010-09-16 |
2011-01-05 |
孙卫东 |
一种盐酸右哌甲酯双释放制剂及其制备方法
|
WO2012040710A2
(en)
*
|
2010-09-24 |
2012-03-29 |
Case Western Reserve University |
Stabilized nanobubbles for diagnostic and therapeutic applications
|
BR112013007640A2
(pt)
|
2010-10-01 |
2017-09-26 |
Aptalis Pharma Ltd |
"composição, forma de dosagem, pacote, processo para a preparação da composição, processo para a preparação da forma de dosagem, método para tratamento ou prevenção de um distúrbio ou afecção associada a uma defeciência de enzima digestiva, método de terapia de substituição de enzima pacnreática e método para aperfeiçoar resultados nutricionais e de crescimento"
|
AU2011338530B2
(en)
|
2010-12-06 |
2017-06-15 |
Follica, Inc. |
Methods for treating baldness and promoting hair growth
|
WO2012080050A1
(en)
|
2010-12-14 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Solid forms of a phenoxybenzenesulfonyl compound
|
CN103338753A
(zh)
|
2011-01-31 |
2013-10-02 |
细胞基因公司 |
胞苷类似物的药物组合物及其使用方法
|
US9353100B2
(en)
|
2011-02-10 |
2016-05-31 |
Idenix Pharmaceuticals Llc |
Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
|
US8287903B2
(en)
|
2011-02-15 |
2012-10-16 |
Tris Pharma Inc |
Orally effective methylphenidate extended release powder and aqueous suspension product
|
US8927010B2
(en)
|
2011-03-23 |
2015-01-06 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
US9603809B2
(en)
|
2011-03-23 |
2017-03-28 |
Ironshore Pharmaceuticals & Development, Inc. |
Methods of treatment of attention deficit hyperactivity disorder
|
US9283214B2
(en)
|
2011-03-23 |
2016-03-15 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
US11241391B2
(en)
|
2011-03-23 |
2022-02-08 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
MX2021000431A
(es)
|
2011-03-23 |
2022-10-28 |
Ironshore Pharmaceuticals & Dev Inc |
Metodos y composiciones para el tratamiento de trastorno por deficit de atencion.
|
US10905652B2
(en)
|
2011-03-23 |
2021-02-02 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
US9119809B2
(en)
|
2011-03-23 |
2015-09-01 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
US10292937B2
(en)
|
2011-03-23 |
2019-05-21 |
Ironshore Pharmaceuticals & Development, Inc. |
Methods of treatment of attention deficit hyperactivity disorder
|
US8916588B2
(en)
|
2011-03-23 |
2014-12-23 |
Ironshore Pharmaceuticals & Development, Inc. |
Methods for treatment of attention deficit hyperactivity disorder
|
US9498447B2
(en)
|
2011-03-23 |
2016-11-22 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
CA2830948A1
(en)
*
|
2011-03-25 |
2012-10-04 |
Selecta Biosciences, Inc. |
Osmotic mediated release synthetic nanocarriers
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
CN103458859A
(zh)
|
2011-04-07 |
2013-12-18 |
宝洁公司 |
具有增强的聚丙烯酸酯微胶囊的沉积的个人清洁组合物
|
WO2012138690A2
(en)
|
2011-04-07 |
2012-10-11 |
The Procter & Gamble Company |
Conditioner compositions with increased deposition of polyacrylate microcapsules
|
MX2013010983A
(es)
|
2011-04-07 |
2013-10-30 |
Procter & Gamble |
Composiciones de champu con deposito mejorado de microcapsulas de poliacrilato.
|
US8741885B1
(en)
|
2011-05-17 |
2014-06-03 |
Mallinckrodt Llc |
Gastric retentive extended release pharmaceutical compositions
|
US8858963B1
(en)
|
2011-05-17 |
2014-10-14 |
Mallinckrodt Llc |
Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
|
US9050335B1
(en)
|
2011-05-17 |
2015-06-09 |
Mallinckrodt Llc |
Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
|
EP2736537A4
(de)
|
2011-07-29 |
2015-04-15 |
Selecta Biosciences Inc |
Synthetische nanotransporter zur erzeugung humoraler und cytotoxischer t-lymphocy (ctl)-immunreaktionen
|
JP6004549B2
(ja)
|
2011-08-08 |
2016-10-12 |
アプタリス ファーマ リミテッドAptalis Pharma Limited |
消化酵素を含む組成物の溶出試験の方法
|
US9512096B2
(en)
|
2011-12-22 |
2016-12-06 |
Knopp Biosciences, LLP |
Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
|
CN102429884A
(zh)
*
|
2011-12-29 |
2012-05-02 |
天津市嵩锐医药科技有限公司 |
盐酸哌甲酯口腔崩解药物组合物
|
AU2013205306B2
(en)
|
2012-03-16 |
2015-09-17 |
Axikin Pharmaceuticals, Inc. |
3,5-diaminopyrazole kinase inhibitors
|
US9233491B2
(en)
|
2012-05-01 |
2016-01-12 |
Johnson & Johnson Consumer Inc. |
Machine for production of solid dosage forms
|
US9511028B2
(en)
|
2012-05-01 |
2016-12-06 |
Johnson & Johnson Consumer Inc. |
Orally disintegrating tablet
|
US9445971B2
(en)
|
2012-05-01 |
2016-09-20 |
Johnson & Johnson Consumer Inc. |
Method of manufacturing solid dosage form
|
US9867880B2
(en)
|
2012-06-13 |
2018-01-16 |
Atrium Medical Corporation |
Cured oil-hydrogel biomaterial compositions for controlled drug delivery
|
KR20150027800A
(ko)
|
2012-06-15 |
2015-03-12 |
고에키 자이단 호징 센탄 이료 신코 자이단 |
경도 인지 장해의 예방 및/또는 치료제
|
WO2014011830A1
(en)
|
2012-07-12 |
2014-01-16 |
Mallinckrodt Llc |
Extended release, abuse deterrent pharmaceutical compositions
|
US20140161879A1
(en)
*
|
2012-07-31 |
2014-06-12 |
Zogenix, Inc. |
Treating pain in patients with hepatic impairment
|
US10322120B2
(en)
|
2012-07-31 |
2019-06-18 |
Persion Pharmaceuticals Llc |
Treating pain in patients with hepatic impairment
|
ES2717469T3
(es)
|
2012-08-15 |
2019-06-21 |
Tris Pharma Inc |
Comprimido masticable de metilfenidato de liberación prolongada
|
US9662313B2
(en)
|
2013-02-28 |
2017-05-30 |
Knopp Biosciences Llc |
Compositions and methods for treating amyotrophic lateral sclerosis in responders
|
CN105120659A
(zh)
|
2013-03-15 |
2015-12-02 |
度瑞公司 |
用于降低溶解可变性的具有流变改性剂的组合物
|
RU2015146324A
(ru)
|
2013-03-29 |
2017-05-15 |
Вокхардт Лимитед |
Фармацевтические композиции модифицированного высвобождения дексметилфенидата или его солей
|
US10434194B2
(en)
|
2013-06-20 |
2019-10-08 |
Case Western Reserve University |
PSMA targeted nanobubbles for diagnostic and therapeutic applications
|
EP3019167B1
(de)
|
2013-07-12 |
2021-02-17 |
Knopp Biosciences LLC |
Behandlung eines erhöhten spiegels von eosinophilen und/oder basophilen
|
US9468630B2
(en)
|
2013-07-12 |
2016-10-18 |
Knopp Biosciences Llc |
Compositions and methods for treating conditions related to increased eosinophils
|
RU2679832C2
(ru)
|
2013-08-09 |
2019-02-13 |
Аллерган Фармасьютикалз Интернэйшнл Лимитед |
Композиция пищеварительных ферментов, подходящая для энтерального введения
|
AU2014306683B2
(en)
|
2013-08-13 |
2017-10-12 |
Knopp Biosciences Llc |
Compositions and methods for treating plasma cell disorders and B-cell prolymphocytic disorders
|
CA2921381A1
(en)
|
2013-08-13 |
2015-02-19 |
Knopp Biosciences Llc |
Compositions and methods for treating chronic urticaria
|
NZ631142A
(en)
|
2013-09-18 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
|
US20160229866A1
(en)
|
2013-09-20 |
2016-08-11 |
Idenix Pharmaceuticals Inc. |
Hepatitis c virus inhibitors
|
US10987313B2
(en)
|
2013-10-07 |
2021-04-27 |
Impax Laboratories, Llc |
Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
|
KR102266091B1
(ko)
|
2013-10-07 |
2021-06-17 |
임팩스 라보라토리즈, 인코포레이티드 |
레보도파 및/또는 레보도파의 에스테르의 점막-점착성, 제어 방출형 제제 그리고 이의 용도
|
WO2015065547A1
(en)
|
2013-10-31 |
2015-05-07 |
Cima Labs Inc. |
Immediate release abuse-deterrent granulated dosage forms
|
WO2015065497A1
(en)
*
|
2013-11-04 |
2015-05-07 |
Schultz Jack William |
Treatment of cognitive, emotional and mental ailments and disorders
|
CA2936216C
(en)
|
2014-01-10 |
2021-10-26 |
Johnson & Johnson Consumer Inc. |
Process for making tablet using radiofrequency and lossy coated particles
|
WO2015134560A1
(en)
|
2014-03-05 |
2015-09-11 |
Idenix Pharmaceuticals, Inc. |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
JP6568926B2
(ja)
|
2014-03-20 |
2019-08-28 |
カペラ セラピューティクス,インコーポレーテッド |
癌の治療のためのerbbチロシンキナーゼ阻害剤としてのベンゾイミダゾール誘導体
|
TWI683813B
(zh)
|
2014-03-20 |
2020-02-01 |
美商卡佩拉醫療公司 |
苯并咪唑衍生物及其醫藥組合物及使用方法
|
AU2015275860A1
(en)
|
2014-06-19 |
2016-11-03 |
Aptalis Pharma Ltd. |
Methods for removing viral contaminants from pancreatic extracts
|
KR101686986B1
(ko)
|
2014-07-28 |
2016-12-16 |
에스케이케미칼주식회사 |
류프로라이드를 포함하는 속효성과 지속성을 동시에 갖는 약제학적 조성물
|
US9132096B1
(en)
|
2014-09-12 |
2015-09-15 |
Alkermes Pharma Ireland Limited |
Abuse resistant pharmaceutical compositions
|
EP3193845A1
(de)
|
2014-09-19 |
2017-07-26 |
The Procter and Gamble Company |
Darreichungsformen von phenylephrin mit gepulster freisetzung
|
CA2936746C
(en)
|
2014-10-31 |
2017-06-27 |
Purdue Pharma |
Methods and compositions particularly for treatment of attention deficit disorder
|
GB201420306D0
(en)
*
|
2014-11-14 |
2014-12-31 |
Bio Images Drug Delivery Ltd |
Compositions
|
WO2016090168A1
(en)
*
|
2014-12-03 |
2016-06-09 |
Velicept Therapeutics, Inc. |
Compositions and methods of using modified release solabegron for lower urinary tract symptoms
|
EA032473B1
(ru)
|
2014-12-23 |
2019-05-31 |
Аксикин Фармасьютикалз, Инк. |
3,5-диаминопиразоловые ингибиторы киназы
|
US11590228B1
(en)
|
2015-09-08 |
2023-02-28 |
Tris Pharma, Inc |
Extended release amphetamine compositions
|
JP2018530585A
(ja)
|
2015-10-16 |
2018-10-18 |
マリナス ファーマシューティカルズ インコーポレイテッド |
ナノ粒子を含む注射可能な神経ステロイド製剤
|
FI3365321T3
(fi)
|
2015-10-23 |
2024-01-02 |
B3Ar Therapeutics Inc |
Solabegron-Zwitterioni ja sen käyttöjä
|
US20170296476A1
(en)
*
|
2016-04-15 |
2017-10-19 |
Grünenthal GmbH |
Modified release abuse deterrent dosage forms
|
US10335405B1
(en)
|
2016-05-04 |
2019-07-02 |
Patheon Softgels, Inc. |
Non-burst releasing pharmaceutical composition
|
EP3463312A4
(de)
*
|
2016-06-03 |
2020-02-05 |
Velicept Therapeutics, Inc. |
Dosierschemata für beta-3-adrenozeptoragonisten und antimuskarinika zur behandlung und vorbeugung von symptomen der unteren harnwege und überaktiver blase
|
BR112019002538A2
(pt)
|
2016-08-11 |
2019-05-21 |
Ovid Therapeutics Inc. |
uso de uma composição farmacêutica compreendendo um modulador alostérico, uso de uma composição farmacêutica compreendendo garboxadol ou um sal farmaceuticamente aceitável do mesmo, e composição farmacêutica para a administração parenteral
|
US10391105B2
(en)
|
2016-09-09 |
2019-08-27 |
Marinus Pharmaceuticals Inc. |
Methods of treating certain depressive disorders and delirium tremens
|
EP3585439A4
(de)
|
2016-11-01 |
2020-07-22 |
Neos Therapeutics, LP |
Wirksame dosierung für kinder zur behandlung von adhd mit methylphenidat
|
US10278930B2
(en)
|
2017-03-16 |
2019-05-07 |
The Procter & Gamble Company |
Method for relieving sinus congestion
|
US10493026B2
(en)
|
2017-03-20 |
2019-12-03 |
Johnson & Johnson Consumer Inc. |
Process for making tablet using radiofrequency and lossy coated particles
|
US10555986B2
(en)
*
|
2017-03-23 |
2020-02-11 |
Instituto De Capacitación E Investigación Del Plás |
Dietary supplement derived from natural prodcuts by hot melt extrusion (HME) processing
|
US11590081B1
(en)
|
2017-09-24 |
2023-02-28 |
Tris Pharma, Inc |
Extended release amphetamine tablets
|
US11020402B2
(en)
|
2018-10-15 |
2021-06-01 |
Axsome Therapeutics, Inc. |
Use of reboxetine to treat narcolepsy
|
US20200147093A1
(en)
|
2018-10-15 |
2020-05-14 |
Axsome Therapeutics, Inc. |
Use of esreboxetine to treat nervous system disorders such as fibromyalgia
|
US10722473B2
(en)
|
2018-11-19 |
2020-07-28 |
Purdue Pharma L.P. |
Methods and compositions particularly for treatment of attention deficit disorder
|
WO2020104955A1
(en)
*
|
2018-11-20 |
2020-05-28 |
Dr. Reddy’S Laboratories Limited |
Pharmaceutical compositions of acotiamide and proton pump inhibitor
|
US11266662B2
(en)
|
2018-12-07 |
2022-03-08 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in prophylaxis and treatment of postpartum depression
|
US11324707B2
(en)
|
2019-05-07 |
2022-05-10 |
Clexio Biosciences Ltd. |
Abuse-deterrent dosage forms containing esketamine
|
WO2021026124A1
(en)
|
2019-08-05 |
2021-02-11 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in treatment of status epilepticus
|
WO2021113834A1
(en)
|
2019-12-06 |
2021-06-10 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in treating tuberous sclerosis complex
|